In VitroEvaluation of the Antimicrobial Activity of Meropenem in Combination with Polymyxin B and Gatifloxacin AgainstPseudomonas aeruginosaandAcinetobacter baumannii

Guelfi, K.C.; Tognim, Maria Cristina Bronharo; Cardoso, Celso Luis; Gales, Ana Cristina; Carrara-Marrone, Floristher Elaine; Garcia, Lourdes Botelho

doi:10.1179/joc.2008.20.2.180

Cited by 20 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For meropenem–polymyxin B combinations ( Figure 6 ), tests were carried out on 99 strains in four studies, and showed a pooled synergy rate of 37.0% (95% CI, 0.0%–100.0%) and heterogeneity ( I 2 ) was 98.1%. 13 , 26 , 39 , 51 Owing to its high heterogeneity, we used the random-effect model for statistical analysis. No isolates were found to be antagonistic.…”

Section: Resultsmentioning

confidence: 99%

Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis

Jiang

2018

IDR

View full text Add to dashboard Cite

PurposeThe main objective of our meta-analysis was to examine the in vitro synergistic effect of meropenem-based combination therapies against Acinetobacter baumannii through a systematic review of the existing literature.MethodsAn extensive search was performed with no restrictions on date of publication, language, and publication type. Our study evaluated the main conclusions drawn from various studies describing the synergistic activity of combination therapies in vitro.ResultsIn this review, 56 published studies were included. Our report included data on 20 types of antibiotics combined with meropenem in 1,228 Acinetobacter baumannii isolates. In time-kill studies, meropenem combined with polymyxin B and rifampicin showed synergy rates of 98.3% (95% CI, 83.7%–100.0%) and 89.4% (95% CI, 57.2%–100.0%), respectively, for Acinetobacter baumannii, modest synergy rates were found for meropenem combined with several antibiotics such as colistin and sulbactam, and no synergy effect was displayed in the combination of meropenem and ciprofloxacin, whereas in checkerboard method, the synergy rates of polymyxin B and rifampicin were 37.0% (95% CI, 0.00%–100.0%) and 56.3% (95% CI, 8.7%–97.8%), respectively.ConclusionWe found that time-kill studies generally identified the greatest synergy, while checkerboard and Etest methods yielded relatively poor synergy rates. Further well-designed in vivo studies should be carried out to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis

Jiang

2018

IDR

View full text Add to dashboard Cite

show abstract

“…indifference as 4≥∑FIC>1 and antagonism as ∑FIC>4 (Fernandez-Cuenca et al, 2003, Guelfi et al, 2008, Kiffer et al, 2005, Timurkaynak et al, 2006, or 4. Synergy as ∑FIC≤0.5; additive as 1≥∑FIC>0.5 and antagonism as ∑FIC≥4 (Manikal et al, 2000), or the combination MIC of one of the antimicrobials is less than its susceptible breakpoint.…”

Section: Methodsmentioning

confidence: 99%

A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii

March

Bratos

2015

Journal of Microbiological Methods

View full text Add to dashboard Cite

“…A recent study in our laboratory demonstrated an indifferent effect for the combination of polymyxin B and meropenem for 80% of the P. aeruginosa strains tested. In addition, no change in MIC values was observed in the meropenem-resistant strains [11].…”

Section: Resultsmentioning

confidence: 98%

“…The drug combination tests were evaluated by the checkerboard method [11] in 96-well microtitre plates (Inlab, São Paulo, Brazil). Polymyxin B and colistin were tested alone and in association with multiples and fractions of the MICs of ceftazidime, cefepime and piperacillin.…”

Section: Evaluation Of the Antimicrobial Activity Of The Combinationsmentioning

confidence: 99%

In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa

Mitsugui

Tognim

Cardoso

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

The emergence of multidrug-resistant (MDR) strains has made it difficult to treat infections caused by Pseudomonas aeruginosa. In order to develop new alternative therapies for the treatment of MDR P. aeruginosa infections, the antimicrobial activities of different antibiotic combinations have been studied in vitro and in vivo. In this study, the in vitro antimicrobial activities of six different combinations of polymyxins and β-lactams against 34 clinical isolates of P. aeruginosa were evaluated. For the combinations tested by the checkerboard method, an indifferent effect was observed for all strains. However, 27 strains (19 MDR) showed reductions in their minimal inhibitory concentration (MIC) for at least one of the antibiotics in the combinations evaluated. Combination with polymyxins resulted in reductions of the β-lactam MICs, with a change in the resistance category to susceptible in eight MDR strains. These results from the in vitro evaluation suggest that combinations of polymyxins and β-lactams may significantly reduce the MICs of the antibiotics tested. These combinations require further evaluation for use in medical practice.

show abstract

In VitroEvaluation of the Antimicrobial Activity of Meropenem in Combination with Polymyxin B and Gatifloxacin AgainstPseudomonas aeruginosaandAcinetobacter baumannii

Cited by 20 publications

References 16 publications

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii

In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa

Contact Info

Product

Resources

About